Several epidemiological studies have demonstrated that copeptin might be used as a prognosis biomarker including predicting neurologic deterioration, risk stratification, and poor outcome (mortality, unfavorable outcome, and recurrence) of stroke [9–13], and the possible mechanism was the copeptin could mirror the hypothalamic-pituitary-adrenal axis as well as the sympathetic nervous system [14], which might promote pathophysiological conditions of stroke. Here, AVP is linked to Stroke.